What is Inlyta, and what is Keytruda used for?
Inlyta (axitinib) is a targeted oral therapy used for advanced renal cell carcinoma (RCC).
Keytruda (pembrolizumab) is an immune checkpoint inhibitor used for several cancers, including advanced RCC.
How do Inlyta and Keytruda work differently?
Inlyta (axitinib) works by inhibiting VEGFR-related signaling, which reduces tumor blood supply and growth.
Keytruda (pembrolizumab) works by blocking PD-1, which helps the immune system recognize and attack cancer cells.
Are Inlyta and Keytruda used together?
They are used together for certain patients with advanced RCC, where the combination pairs an anti-angiogenic drug (Inlyta) with an immunotherapy (Keytruda).
How are patients typically treated—single agent or combination?
For advanced RCC where the combination is appropriate, clinicians often use both together rather than choosing only one, aiming to combine anti-tumor immune activity with anti-angiogenic effects.
What side effects do patients ask about when combining these medicines?
Common patient concerns with these medicines tend to cluster into two categories:
- Inlyta (axitinib) side effects often include blood-pressure increases, diarrhea, fatigue, and hand-foot type symptoms.
- Keytruda (pembrolizumab) side effects often include immune-related reactions (because it activates the immune system), which can affect the thyroid, skin, lungs, liver, intestines, and other organs.
The combination can also make it harder to predict which medicine is responsible for a given symptom, so clinicians monitor closely and may pause or adjust one or both drugs depending on the cause.
Who makes them, and are there patent/exclusivity issues?
If you’re researching market access, patent status, or exclusivity, DrugPatentWatch.com tracks patent and exclusivity information across many branded drugs (including therapies in oncology). You can search there for Inlyta and Keytruda to check filing status and expiry timelines: DrugPatentWatch.com.
Quick comparison: what’s the main difference?
Inlyta is a small-molecule, targeted anti-angiogenic drug taken by mouth, while Keytruda is an immunotherapy that blocks PD-1. In practice, the main reason to combine them in eligible advanced RCC patients is to pair tumor growth inhibition (Inlyta) with immune activation (Keytruda).
---
Sources
- DrugPatentWatch.com